Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer

In total, 70 patients were enrolled into this phase II study, to evaluate the activity of the pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) combination in recurrent ovarian cancer patients. PLD, 30 mg m(−2), was administered on day 1 by 60′ i.v. infusion, followed by GEM, 1000 mg m(−2)...

Full description

Saved in:
Bibliographic Details
Main Authors: D'Agostino, G, Ferrandina, G, Ludovisi, M, Testa, A, Lorusso, D, Gbaguidi, N, Breda, E, Mancuso, S, Scambia, G
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2003
Subjects:
Clinical
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2394291/
https://ncbi.nlm.nih.gov/pubmed/14520442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601284
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items